Analysts Anticipate Blueprint Medicines Co. (NASDAQ:BPMC) Will Post Quarterly Sales of $40.22 Million

Analysts expect Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) to post $40.22 million in sales for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have made estimates for Blueprint Medicines’ earnings, with the highest sales estimate coming in at $53.00 million and the lowest estimate coming in at $30.90 million. Blueprint Medicines […]

Related Keywords

United States ,America ,L Becker Hewes ,Ariel Hurley ,Asset Management North America Corp ,Blueprint Medicines Corporation ,Securities Exchange Commission ,Zacks Investment Research ,Norges Bank ,Blackrock Inc ,Nasdaq ,Walleye Capital ,Blueprint Medicines Co ,William Blair Investment Management ,Citigroup ,Blueprint Medicines ,Get Rating ,Zacks Investment ,Blueprint Medicine ,Investment Research ,Exchange Commission ,Blair Investment Management ,Management North America ,Medicines Corporation ,Nasdaq Bpmc ,Bpmc ,Medical ,Ratings ,Consensus ,